🇺🇸 FDA
Pipeline program

BGB-58067

2025-24

Phase 1 small_molecule active

Quick answer

BGB-58067 for Glioblastoma (GBM) is a Phase 1 program (small_molecule) at BeOne Medicines with 1 ClinicalTrials.gov record(s).

Program details

Company
BeOne Medicines
Indication
Glioblastoma (GBM)
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials